School of Medicine
Showing 11-20 of 53 Results
Instructor, Pediatrics - Stem Cell Transplantation
Bio Dr. Cepika is an immunologist with an extensive background in translational research, autoimmunity, autoinflammation, and human systems immunology. Her goal is to understand the mechanisms governing immunological tolerance, and to leverage this knowledge to cure currently incurable diseases.
Dr. Cepika received her MD degree and a PhD in Immunology from the University of Zagreb School of Medicine in Croatia. There, she focused on the immunomonitoring of patients with lupus, identifying how circulating DNA levels changed with therapy. Subsequently, she joined the lab of Dr. Virginia Pascual at the Baylor Institute for Immunology Research in Dallas, Texas. Dr. Pascual had previously discovered that IL-1beta is a key pathogenic player in systemic juvenile idiopathic arthritis (sJIA), but the immune alterations contributing to IL-1beta-mediated inflammation remained unknown. To address this, Dr. Cepika developed a 3D in vitro stimulation assay to evaluate immune responses of blood leukocytes of pediatric sJIA patients. In combination with integrated bioinformatics analysis, this approach identified aberrant cellular responses, transcriptional pathways and genes that shed new light on immune dysregulation in sJIA. This assay can be further applied to dissect underlying immunopathogenic mechanisms in many human disorders.
Currently, Dr. Cepika is a member of the laboratory of Dr. Maria Grazia Roncarolo, in the Pediatric Division of Stem Cell Biology and Regenerative Medicine at Stanford University School of Medicine. There, she is working to uncover the underlying mechanisms governing type 1 regulatory T (Tr1) cell differentiation and function, and use this knowledge to design Tr1 cell-based therapies for hematopoietic stem cell transplantation, cancer immunotherapy and autoimmunity.
Assistant Professor of Pediatrics (Stem Cell Transplantation)
Current Research and Scholarly Interests Dr. Czechowicz’s research is aimed at understanding how hematopoietic stem cells interact with their microenvironment in order to subsequently modulate these interactions to improve bone marrow transplantation and unlock biological secrets that further enable regenerative medicine broadly. This work can be applied across a variety of disease states ranging from rare genetic diseases, autoimmune diseases, solid organ transplantation, microbiome-augmentation and cancer.
Dr. M Carolina Gallego Iradi
Thymus Research Assistant, Pediatrics - Ped Stem Cell Transplantation
Bio •Currently working in human transcriptomics & immune system since 2017 at Stanford.
• In October 2017 my previous research related to Alzheimer's signs in dolphins got worldwide recognition appearing in tv and newspapers from all around the world such Newsweek, The Times, CBS, Discover, The Chicago Post, Los Angeles Times, Nature, National Geographic Italy (2018) and more. I recently joined to Stanford University (Stem Cell Transplantation and Regenerative Medicine).
• My initial training focused on marine biology, with special emphasis on trace metal pollution. This work, which involved collaborations with different governmental, private (as Venezuelan Oil Company) and University entities (national and international), was well recognized in Venezuela where I received a merit award by the Town Hall of Porlamar (Margarita Island).
• After graduation, I obtained a fellowship to enroll in a Master Degree program in Waste Management at the Universidad Internacional de Andalucia (Spain). My performance in this program allowed me to obtain a very prestigious Biomedicine fellowship (one awarded in all of Latin America) from the Santander-Central-Hispano Bank to begin a PhD in Genetics and Development related to Neuroscience at Universidad de Zaragoza (Spain).
• My PhD studies focused on comparative pathology, demonstrating pathology similar to Alzheimer's Disease in dogs and cetaceans. After a few years of work in academia in Venezuela, I obtained an opportunity to become a post-doctoral fellow at the University of Florida (USA).
• In 2014, I transferred to the Department of Neuroscience to work with Drs. David Borchelt. Since this time, my work has focused on understanding how mutations in Matrin 3 cause ALS and myopathy. In 2016, I was promoted to an entry level faculty position (Assistant Scientist) in the Department of Neuroscience and my goal includeded the use of techniques in genetics,, cellular biology and chemistry to develop a research program that spans basic science to pharmacological application in neuromuscular disorders.
Assistant Professor of Pediatrics (Genetics) and of Pediatrics (Stem Cell Transplantation)
Current Research and Scholarly Interests Dr. Gomez-Ospina is a physician scientist and medical geneticist with a strong interest in the diagnosis and management of genetic diseases.
1) Lysosomal storage diseases:
Her research program is on developing better therapies for a large class of neurodegenerative diseases in children known as lysosomal storage disorders. Her current focus is on developing genome editing of hematopoietic stem cells as a therapeutic approach for these diseases beginning with Mucopolysaccharidosis type 1 and Gaucher disease. She established a genetic approach where therapeutic proteins can be targeted to a single well-characterized place in the genome known as a safe harbor. This approach constitutes a flexible, “one size fits all” approach that is independent of specific genes and mutations. This strategy, in which the hematopoietic system is commandeered to express and deliver therapeutic proteins to the brain can potentially change the current approaches to treating childhood neurodegenerative diseases and pave the way for alternative therapies for adult neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease
2) Point of care ammonia testing
She also works in collaboration with other researchers at Stanford to develop point-of-care testing for serum ammonia levels. Such device will greatly improve the quality of life of children and families with metabolic disorders with hyperammonemia.
3) Gene discovery
Dr Gomez-Ospina lead a multi-institutional collaboration resulting in the discovery of a novel genetic cause of neonatal and infantile cholestatic liver disease. She collaborated in the description of two novel neurologic syndromes caused by mutations in DYRK1 and CHD4.
For more information go to our website: